Intra-Cellular Therapies up as depression drug meets main goal of late-stage study

Intra-Cellular Therapies

16/04/2024 13:33

** Drugmaker Intra-Cellular Therapies' shares  ITCI.O  rise
20% to $78 premarket
    ** Co says its experimental drug to treat major depressive
disorder achieved statistical significance in a late-stage study
    ** Drug given in addition to antidepressants met the main
goal of reducing symptoms of depression measured by a disease
measurement scale compared to placebo at six weeks
     ** Also met key secondary goals of reducing the severity of
the disease, co says
    ** Drug was safe and well-tolerated with most adverse events
being mild to moderate
    ** Major depressive disorder is a common mood disorder with
symptoms of sadness, helplessness and feelings of guilt
    ** Results from the second late-stage study are expected in
Q2 of this year, co says 
    ** Up to last close, stock down 9.6% YTD

 (Reporting by Sneha  S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))